TOP TEN perturbations for 39812_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39812_at
Selected probe(set): 203931_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39812_at (203931_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-3.8956566Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):3.6236954Number of Samples:2 / 2
Experimental | T-cell activation study 4 |
T-cell samples antiCD3 activated for 30hrs. | |
Control | normal resting T-cell sample |
T cells resting for 30h. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):-3.51406Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-3.3574991Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
tumor supernatant activation study 3 / memory T-cell activation study 1
Relative Expression (log2-ratio):-3.2176466Number of Samples:4 / 3
Experimental | tumor supernatant activation study 3 |
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
Control | memory T-cell activation study 1 |
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):3.129942Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):2.8341093Number of Samples:2 / 2
Experimental | T-cell activation study 3 |
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
Control | resting CD4 T-lymphocyte (crude fraction) sample |
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):2.8020878Number of Samples:20 / 19
Experimental | atopic dermatitis study 12 (non-lesional; adults) |
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (non-lesional; children) |
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):2.7961369Number of Samples:2 / 3
Experimental | glioma study 16 (LN-18) |
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):2.7530746Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |